Cardiol Therapeutics (TSE:CRDL) Posts Earnings Results

Cardiol Therapeutics (TSE:CRDL) announced its quarterly earnings results on Thursday. The company reported C($0.11) EPS for the quarter, FiscalAI reports.

Cardiol Therapeutics Price Performance

Shares of CRDL stock traded down C$0.03 on Friday, hitting C$1.44. 26,778 shares of the stock traded hands, compared to its average volume of 139,720. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.55 and a quick ratio of 6.84. The firm has a 50 day simple moving average of C$2.04 and a two-hundred day simple moving average of C$1.81. The firm has a market cap of C$174.98 million, a price-to-earnings ratio of -4.24 and a beta of 0.14. Cardiol Therapeutics has a 52 week low of C$1.23 and a 52 week high of C$3.23.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.